1. Home
  2. LDTC vs GANX Comparison

LDTC vs GANX Comparison

Compare LDTC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LDTC
  • GANX
  • Stock Information
  • Founded
  • LDTC 2007
  • GANX 2017
  • Country
  • LDTC Canada
  • GANX United States
  • Employees
  • LDTC N/A
  • GANX N/A
  • Industry
  • LDTC Blank Checks
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LDTC Finance
  • GANX Health Care
  • Exchange
  • LDTC Nasdaq
  • GANX Nasdaq
  • Market Cap
  • LDTC 24.7M
  • GANX 31.5M
  • IPO Year
  • LDTC N/A
  • GANX 2021
  • Fundamental
  • Price
  • LDTC $0.75
  • GANX $1.16
  • Analyst Decision
  • LDTC Buy
  • GANX Strong Buy
  • Analyst Count
  • LDTC 2
  • GANX 4
  • Target Price
  • LDTC $5.00
  • GANX $8.25
  • AVG Volume (30 Days)
  • LDTC 16.8K
  • GANX 298.5K
  • Earning Date
  • LDTC 05-15-2024
  • GANX 08-08-2024
  • Dividend Yield
  • LDTC N/A
  • GANX N/A
  • EPS Growth
  • LDTC N/A
  • GANX N/A
  • EPS
  • LDTC N/A
  • GANX N/A
  • Revenue
  • LDTC $7,930,323.00
  • GANX N/A
  • Revenue This Year
  • LDTC N/A
  • GANX $1,009.10
  • Revenue Next Year
  • LDTC $46.76
  • GANX N/A
  • P/E Ratio
  • LDTC N/A
  • GANX N/A
  • Revenue Growth
  • LDTC N/A
  • GANX N/A
  • 52 Week Low
  • LDTC $0.71
  • GANX $1.11
  • 52 Week High
  • LDTC $11.20
  • GANX $5.33
  • Technical
  • Relative Strength Index (RSI)
  • LDTC 28.47
  • GANX 35.19
  • Support Level
  • LDTC $0.82
  • GANX $1.22
  • Resistance Level
  • LDTC $0.93
  • GANX $1.32
  • Average True Range (ATR)
  • LDTC 0.11
  • GANX 0.08
  • MACD
  • LDTC 0.03
  • GANX 0.04
  • Stochastic Oscillator
  • LDTC 0.03
  • GANX 17.24

About LDTC LeddarTech Holdings Inc.

LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: